GLOBAL CANCER TECHNOLOGY ANNOUNCES RESEARCH COLLABORATION WITH UNIVERSITY OF NEW MEXICO ON GCT-007 AND GCT-008 IN GLIOBLASTOMA
Global Cancer Technology (GCT), a preclinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced a research collaboration with The University of New Mexico (UNM).
USPTO Grants Patent Protection for Global Cancer Technology’s Novel PI3K Inhibitor GCT-007
FOR IMMEDIATE RELEASE GLOBAL CANCER TECHNOLOGY RECEIVES U.S. PATENT FOR
Can Blocking the PI3K Pathway Help Fight Treatment-Resistant Thyroid Cancer?
FOR IMMEDIATE RELEASE GLOBAL CANCER TECHNOLOGY LAUNCHES THYROID CANCER RESEARCH
New Preclinical Data: GCT-007 + Immune Checkpoint Inhibitors Show Synergistic Activity in Childhood Diffuse Midline Glioma
KEY MESSAGE: Global Cancer Technology reports compelling synergy between its
GCT-007 Plus Tamoxifen Synergistic Effect Treating Endocrine Therapy-Resistant Breast Cancer
For Immediate Release Contact: info@globalcancertechnology.com San Diego, CA – July
Global Cancer Technology Appoints Dr. Sanjeev Thohan as Chief Development Officer
Global Cancer Technology is a preclinical-stage biopharmaceutical company focused on advancing novel therapeutics for oncology. The company is currently raising investment capital to support its planned Phase I clinical trial.
Global Cancer Technology Secures Full Ownership of Groundbreaking Cancer-Fighting Patents
Global Cancer Technology has acquired full patent ownership for two potentially life-saving cancer treatments from Neuropore Therapies.